BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis

BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis

Source: 
BioSpace
snippet: 
  • Full rights returned following Exelixis' corporate restructuring announced January 07, 2024
  • Collaboration generated novel targets and antibodies for use in immuno-oncology therapeutics